Vaccines averted the highest rate of deaths during the Delta period, with 68% of deaths averted.
Plaque growth can lead to a higher risk of heart attack, stroke, and other life-threatening cardiovascular events for as long as 1 year.
Post-exertional malaise, or exercise intolerance, was seen in 36% of those with long COVID.
Get weekly COVD-19 updates in your inbox.
Catch the latest episode!
Top COVID FAQs
By CIDRAP & other experts
Read all 7 reports
The comments prompted swift and sharp criticism among some public health experts.
"We think these principles can be applied to the next respiratory viral epidemic," a committee chair said of the SHEA statement.
Moderna's 2-strain booster triggered stronger antibody responses that its original booster did.
About 9 months after COVID-19 infection, 19% of nonhospitalized adult patients in a German cohort had fatigue, 26% had mild cognitive impairment ("brain fog"), and 1% had moderate cognitive dysfunction, according to a multicenter study.
The study, published late last week in EClinicalMedicine, also showed that the incidence and risk factors for fatigue and cognitive impairment differed by age-group.
One in three unvaccinated COVID-19 survivors in a Spanish cohort had no detectable SARS-CoV-2 antibodies nearly 1 year after infection, according to a prospective study published today in BMC Medicine.
After 2 years, 12% had lingering symptoms and 8% had new-onset or worsening symptoms.
The report spares no one the responsibility—including the public—for millions of preventable deaths.
South African researchers report waning monovalent (single-strain) COVID-19 vaccine booster effectiveness against the Omicron subvariants, with estimated efficacy falling to 50% against the BA.1/BA.2 and 47% against BA.4/BA.5 as early as 3 or 4 months after vaccination.
Older COVID-19 survivors may be at a 69% higher risk of developing Alzheimer's within 1 year.
In US news, practitioners describe issues with vaccination due to multiple vaccine products and confusing immunization schedules.
